Surrozen, Inc. Share Price & Technical Analysis
SRZN · $26.37 (-2.66%)
Healthcare / Biotechnology
$26.37
-2.66%
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, w…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-21% return in May, -5% avg return in past 3 year May month.
20% return in 2026, 70% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -7% | 30% | 5% | 13% | -21% | – | – | – | – | – | – | – | 20% |
| 25 | -18% | 5% | 4% | -6% | -23% | 14% | 12% | 26% | 8% | 8% | 16% | 37% | 82% |
| 24 | -16% | 60% | 24% | -24% | 6% | -9% | -26% | 34% | 25% | 14% | -10% | 20% | 96% |
| 23 | 25% | 36% | -40% | 1% | 2% | -13% | 35% | -31% | -9% | -25% | 26% | 25% | 33% |
| 22 | -62% | 28% | -1% | -16% | -5% | 3% | -22% | -2% | -22% | 13% | -73% | -3% | -164% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$341.69M
P/E ratio
—
52W high
$35.00
52W low
$7.45
Volume
53,080
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Surrozen, Inc. share price today?
- Surrozen, Inc. (SRZN) last traded around $26.37 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SRZN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SRZN. Download the app for real-time alerts.
- How can I analyze Surrozen, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.